SPY305.90+0.35 0.11%
DIA256.42+1.15 0.45%
IXIC9,500.62-51.43 -0.54%

Avadel Pharmaceuticals Q1 EPS $(0.020) Beats $(0.240) Estimate, Sales $12.240M Beat $10.150M Estimate

Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.020) per share which beat the analyst consensus estimate of $(0.240) by 91.67 percent. This is a 92.86 percent increase over losses of $(0.280) per

Benzinga · 05/11/2020 11:20

Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.020) per share which beat the analyst consensus estimate of $(0.240) by 91.67 percent. This is a 92.86 percent increase over losses of $(0.280) per share from the same period last year. The company reported quarterly sales of $12.240 million which beat the analyst consensus estimate of $10.150 million by 20.59 percent. This is a 25.53 percent decrease over sales of $16.437 million the same period last year.